Vetoquinol | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
299,727.00
315,298.00
342,612.00
350,354.00
352,173.00
367,941
Cost of Goods Sold (COGS) incl. D&A
188,401.00
198,767.00
221,644.00
217,920.00
242,682.00
253,348
Gross Income
111,326.00
116,531.00
120,968.00
132,434.00
109,491.00
114,593
SG&A Expense
78,361.00
81,618.00
82,169.00
90,312.00
64,818.00
66,631
EBIT
28,306.00
27,428.00
32,675.00
36,904.00
40,312.00
43,315
Unusual Expense
427.00
1,103.00
4,795.00
2,105.00
362.00
231
Non Operating Income/Expense
19.00
10,386.00
4,065.00
690.00
688.00
908
Interest Expense
579.00
601.00
672.00
594.00
496.00
354
Pretax Income
28,527.00
37,656.00
32,603.00
35,937.00
39,180.00
44,077
Income Tax
4,942.00
11,884.00
8,443.00
7,970.00
4,228.00
7,666
Equity in Affiliates
-
-
-
137.00
114.00
185
Consolidated Net Income
23,585.00
25,772.00
24,160.00
27,830.00
34,838.00
36,226
Net Income
23,580.00
25,766.00
24,156.00
27,827.00
34,831.00
36,259
Net Income After Extraordinaries
23,580.00
25,766.00
24,156.00
27,827.00
34,831.00
36,259
Net Income Available to Common
23,580.00
25,766.00
24,156.00
27,827.00
34,831.00
36,259
EPS (Basic)
1.99
2.17
2.04
2.35
2.94
3.06
Basic Shares Outstanding
11,841.00
11,863.60
11,864.30
11,854.50
11,856.30
11,840.80
EPS (Diluted)
1.98
2.17
2.04
2.35
2.94
3.06
Diluted Shares Outstanding
11,880.30
11,863.60
11,864.30
11,854.50
11,856.30
11,840.80
EBITDA
39,874.00
40,273.00
46,262.00
50,416.00
52,532.00
56,153
Other Operating Expense
4,659.00
7,485.00
6,124.00
5,218.00
4,361.00
4,647
Non-Operating Interest Income
1,246.00
1,546.00
1,330.00
1,042.00
414.00
439
Minority Interest Expense
5.00
6.00
4.00
3.00
7.00
33

About Vetoquinol

View Profile
Address
34, rue du Chêne Sainte-Anne
Lure Franche-Comte 70200
France
Employees -
Website http://www.vetoquinol.com
Updated 07/08/2019
Vétoquinol SA engages in designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific regions. It is a player in the animal health sector serving both the livestock such as cattle and pigs and pet dogs and cats markets. The company operates through the following segments: Europe, Americas, and Asia Pacific and Rest of the World.